We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

The Orbit and the Brain—Reply

Helga D. Munch-Petersen, MD1,2; Peter K. Rasmussen, MD, PhD2; Steffen Heegaard, MD, DMSc2,3
[+] Author Affiliations
1Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark
2Eye Pathology Institute, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
3Department of Ophthalmology, Glostrup University Hospital, Glostrup, Denmark
JAMA Ophthalmol. 2015;133(6):727-728. doi:10.1001/jamaophthalmol.2015.0367.
Text Size: A A A
Published online


In Reply We read with interest Ferreri’s comments on our multicenter work on OA-DLBCL.1 We are pleased to have the opportunity to contribute with further information regarding this uncommon subcategory of extranodal non-Hodgkin lymphoma.

Current information concerning clinical and histopathological characteristics of OA-DLBCL is sparse because investigations often are limited to series of ocular adnexal lymphomas covering a wider range of subtypes.2 Our retrospective international study included 100 patients with OA-DLBCL from 6 eye cancer centers during a 30-year period.1 The nature of this design left us with a relatively large cohort as compared with others, but at the same time we adopted the difficulties of selection bias inherent to our heterogeneous study population.1 Another important bias was related to the fact that staging procedures (eg, Ann Arbor staging) were far more exhaustive in the latter half of the study period.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2015
Andrés J. M. Ferreri, MD
1Unit of Lymphoid Malignancies, Division of Onco-hematological Medicine, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy
JAMA Ophthalmol. 2015;133(6):726-727. doi:10.1001/jamaophthalmol.2015.0365.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...